Share Name Share Symbol Market Type Share ISIN Share Description
Bonesupport Holding Ab LSE:0RQO London Ordinary Share SE0009858152 BONESUPPORT HOLDING ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 12.12 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
- - - - 0

BONESUPPORT Appoints Michael Roth as General Manager & Executive Vice President Commercial Operations North America

29/04/2020 4:10pm

PR Newswire (US)

Bonesupport Holding Ab (LSE:0RQO)
Historical Stock Chart

From Apr 2020 to Oct 2020

Click Here for more Bonesupport Holding Ab Charts.

LUND, Sweden, April 29, 2020 /PRNewswire/ -- BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries announces a change in its leadership team that will take place June 1, 2020. Michael Roth starts in the position as the company's General Manager & Executive Vice President Commercial Operations North America. Michael has more than 20 years of experience within the orthopedic sector with both direct and distributor-based sales management. Michael has a solid leadership experience from both sales and marketing and from small as well as large companies, amongst them Wright Medical Technology, Microport Orthopedics and Howmedica.

"Michael Roth is the leader we need on the American market in order to take BONESUPPORT to the next level. His experience together with his leadership and capability to develop high performing, dynamic teams will be a contributing factor to our continued success on the important US market and with the coming launch of CERAMENT G," said Emil Billbäck, CEO at BONESUPPORT.

For more information contact:


Emil Billbäck, CEO
+46 (0) 46 286 53 70

Håkan Johansson, CFO

Cord Communications
Charlotte Stjerngren


BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient's own bone and have the capability of eluting drugs. BONESUPPORT's bone graft substitutes are based on the patented technology platform CERAMENT. The Company is conducting several clinical studies to further demonstrate the clinical and health economic benefits that its products deliver and a Premarket approval filing with the FDA (USA) for CERAMENT G is planned in 2021. The Company is based in Lund, Sweden, and the net sales amounted to SEK 155 million in 2019. Please visit for more information.

BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.

This information was brought to you by Cision,c3100496

The following files are available for download:


Cision View original content:

SOURCE Bonesupport Holding AB

Copyright 2020 PR Newswire

1 Year Bonesupport Holding Ab Chart

1 Year Bonesupport Holding Ab Chart

1 Month Bonesupport Holding Ab Chart

1 Month Bonesupport Holding Ab Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201027 08:47:14